H.C. Wainwright lowers Compass Pathways (CMPS) price target to $40 from $45, maintains Buy rating. No further development planned in anorexia nervosa post Phase 2 trial completion. Indication removed from model post Q2 report.

TipRanks Premium offers investing tools, data, and analyst insights at 50% off for confident investing.

TheFly provides real-time, market-moving financial news. Visit for more information.

Find top stocks recommended by analysts on TipRanks.

For more information on Compass Pathways (CMPS), refer to Disclaimer & Disclosure or Report an Issue on TipRanks.

Read more at Yahoo Finance: Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright